Q2 25 EPS
$1.44
BEAT +42.31%
Est. $1.01
Q2 25 Revenue
$825.4M
BEAT +8.37%
Est. $761.7M
vs S&P Since Q2 25
-28.1%
TRAILING MARKET
BMRN -10.1% vs S&P +18.0%
Market Reaction
Did BMRN Beat Earnings? Q2 2025 Results
BioMarin delivered a standout second quarter for fiscal 2025, posting non-GAAP diluted EPS of $1.44 against a consensus estimate of $1.01, a beat of 42.31%, while revenue of $825.41 million topped expectations by 8.37% and grew 15.9% year-over-year. … Read more BioMarin delivered a standout second quarter for fiscal 2025, posting non-GAAP diluted EPS of $1.44 against a consensus estimate of $1.01, a beat of 42.31%, while revenue of $825.41 million topped expectations by 8.37% and grew 15.9% year-over-year. The driving force behind the results was broad-based portfolio momentum, with VOXZOGO, BioMarin's skeletal condition therapy, generating $221 million in quarterly revenue, up 20% year-over-year, as new patient initiations accelerated across all regions and the drug reached patients in 51 countries. Enzyme Therapies added $555 million, lifted by strong performances from PALYNZIQ and VIMIZIM. Profitability expanded sharply, with non-GAAP operating margin reaching 39.9%. Early Phase 1 data for BMN 333, a potential long-term successor to VOXZOGO, showed encouraging pharmacokinetic results, with a registration-enabling study planned for 2026. Management raised full-year 2025 guidance, now targeting revenue of $3.13 billion to $3.20 billion and non-GAAP diluted EPS of $4.40 to $4.55.
Key Takeaways
- • Strong 20% year-over-year VOXZOGO revenue growth from new patients initiating therapy across all regions
- • Enzyme Therapies revenue growth of 15% driven by increased patient demand and timing of government orders
- • Lower R&D expenses from re-prioritization of investments following 2024 portfolio strategy review
- • Lower SG&A on GAAP basis due to absence of 2024 severance and restructuring costs
- • GAAP operating margin expanded 16.6 percentage points to 33.5%; Non-GAAP operating margin expanded 8.7 percentage points to 39.9%
BMRN YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
BMRN Revenue by Segment
With YoY comparisons, source: SEC Filings
“We were very pleased with our second quarter performance across all aspects of the business, including strong growth, exciting pipeline progress, and delivery of our business development strategy.”
— Alexander Hardy, Q2 2025 Earnings Press Release
BMRN Earnings Trends
BMRN vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BMRN EPS Trend
Earnings per share: estimate vs actual
BMRN Revenue Trend
Quarterly revenue: estimate vs actual
BMRN Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $0.91 | $0.76 | -16.86% | $766.2M | +1.93% |
| Q4 25 MISS FY | $0.56 | $0.46 | -17.95% | $874.6M | +4.73% |
| FY Full Year | — | $3.15 | — | $3.22B | — |
| Q3 25 MISS | $0.32 | $0.12 | -62.50% | $776.1M | -0.52% |
| Q2 25 BEAT | $1.01 | $1.44 | +42.31% | $825.4M | +8.37% |
| Q1 25 BEAT | $0.95 | $1.13 | +18.87% | $745.1M | +0.91% |